Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Chitogenx Inc C.CHGX

Alternate Symbol(s):  CHNXF

ChitogenX Inc. is a Canada-based clinical-stage regenerative medicine company. The Company is engaged in the development of therapeutic tissue repair technologies to improve tissue healing. The Company is committed to the clinical development of its proprietary RESTORE technology platform, a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various musculoskeletal conditions. Ortho-R, its lead Chitosan-PRP hybrid biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, and cartilage such as the meniscus. Its other formulations are being developed to leverage the technology's performance characteristics, such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease.


CSE:CHGX - Post by User

Chitogenx Inc > Positive Histology Results From Pivotal Preclinical study
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(91)
•••
Comment by RockLobster1on Sep 11, 2020 2:06pm
167 Views
Post# 31543689

RE:RE:RE:Positive Histology Results From Pivotal Preclinical study

RE:RE:RE:Positive Histology Results From Pivotal Preclinical studyThanks for your detailed analysis...  Looks like the market is agreeing with you, been slowly moving up pennt by penny ... and then today a big jump.

So things are looking positive, looks like we are finally getting noticed out there.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities